Haematology 2018

Nivolumab in R/R HL (CA-209-039): Initial Responses and Response Duration

Phase I trial of nivolumab in patients with relapsed or refractory cHL

cHL (n = 23)

76 Weeks

Overall response, n (%)

20 (87)

Partial response rate, n (%)

15 (65)

Complete response rate, n (%)

5 (22)

24-week progression-free survival, %

87%

Duration of response, median (range)

NR (18–82+)

R/R, relapsed or refractory

Ansell SM, et al. N Engl J Med. 2015;372(4):311-319.